Naviter Wealth LLC reduced its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 79.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,227 shares of the company's stock after selling 68,248 shares during the period. Naviter Wealth LLC's holdings in Takeda Pharmaceutical were worth $228,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also made changes to their positions in the company. PNC Financial Services Group Inc. raised its holdings in Takeda Pharmaceutical by 6.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 58,709 shares of the company's stock worth $777,000 after buying an additional 3,392 shares during the period. Generali Investments CEE investicni spolecnost a.s. bought a new position in Takeda Pharmaceutical during the 4th quarter valued at $132,000. West Family Investments Inc. grew its holdings in Takeda Pharmaceutical by 87.7% during the 4th quarter. West Family Investments Inc. now owns 33,468 shares of the company's stock valued at $443,000 after buying an additional 15,638 shares in the last quarter. Callan Family Office LLC purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter worth about $264,000. Finally, Lindbrook Capital LLC increased its stake in shares of Takeda Pharmaceutical by 65.0% during the fourth quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after buying an additional 2,029 shares during the period. Institutional investors and hedge funds own 9.17% of the company's stock.
Takeda Pharmaceutical Stock Performance
TAK stock traded up $0.10 during trading on Thursday, reaching $15.03. The stock had a trading volume of 1,594,760 shares, compared to its average volume of 1,822,516. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a 52 week low of $12.57 and a 52 week high of $15.22. The stock's 50 day moving average is $13.69 and its two-hundred day moving average is $13.91. The firm has a market cap of $47.81 billion, a PE ratio of 37.56, a PEG ratio of 0.24 and a beta of 0.46.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, equities analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.
About Takeda Pharmaceutical
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Read More
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
